| Literature DB >> 27803808 |
Carlotta Mainini1, Patrícia Fs Rebelo1, Roberta Bardelli1, Besa Kopliku1, Sara Tenconi2, Stefania Costi3, Claudio Tedeschi1, Stefania Fugazzaro1.
Abstract
Surgical resection appears to be the most effective treatment for early-stage non-small cell lung cancer. Recent studies suggest that perioperative pulmonary rehabilitation improves functional capacity, reduces mortality and postoperative complications and enhances recovery and quality of life in operated patients. Our aim is to analyse and identify the most recent evidence-based physical exercise interventions, performed before or after surgery. We searched in MEDLINE, EMBASE, CINAHL, Cochrane Library and PsycINFO. We included randomised controlled trials aimed at assessing efficacy of exercise-training programmes; physical therapy interventions had to be described in detail in order to be reproducible. Characteristics of studies and programmes, results and outcome data were extracted. Six studies were included, one describing preoperative rehabilitation and three assessing postoperative intervention. It seems that the best preoperative physical therapy training should include aerobic and strength training with a duration of 2-4 weeks. Although results showed improvement in exercise performance after preoperative pulmonary rehabilitation, it was not possible to identify the best preoperative intervention due to paucity of clinical trials in this area. Physical training programmes differed in every postoperative study with conflicting results, so comparison is difficult. Current literature shows inconsistent results regarding preoperative or postoperative physical exercise in patients undergoing lung resection. Even though few randomised trials were retrieved, treatment protocols were difficult to compare due to variability in design and implementation. Further studies with larger samples and better methodological quality are urgently needed to assess efficacy of both preoperative and postoperative exercise programmes.Entities:
Keywords: Pulmonary rehabilitation; exercise; lung cancer; perioperative rehabilitation; systematic review
Year: 2016 PMID: 27803808 PMCID: PMC5077072 DOI: 10.1177/2050312116673855
Source DB: PubMed Journal: SAGE Open Med ISSN: 2050-3121
Figure 1.Flow chart of study selection.
Study characteristics.
| Reference | PRE/POST intervention | Patients | Type of surgery | Demographic characteristics of patients | |
|---|---|---|---|---|---|
| Age (mean ± SD years) | |||||
| IG | CG | ||||
| Stefanelli et al.[ | PRE | 40 | 100% thoracotomy | 65.5 ± 7.4 | 64.8 ± 7.3 |
| Arbane et al.[ | POST | 131 | 70.3% thoracotomy, 29.7% VATS | 67 ± 11 | 68 ± 11 |
| Brocki et al.[ | POST | 78 | 76.9% thoracotomy, 23.1% VATS | 64 ± 10 | 65 ± 9 |
| Edvardsen et al.[ | POST | 61 | 83.6% thoracotomy, 16.4% VATS | 64.4 ± 9.3 | 65.9 ± 8.5 |
| Cavalheri et al.[ | POST | 17 | 47% thoracotomy, 53% VATS | 66 ± 10 | 68 ± 9 |
| Hoffman et al.[ | POST | 87 | 90% thoracotomy, 10% VATS | 67.4 ± 9.7 | 65.6 ± 10.1 |
PRE: preoperative; POST: postoperative; SD: standard deviation; IG: intervention group; CG: control group; VATS: video-assisted thoracoscopic surgery.
Figure 2.Risk of bias analysis of preoperative study.
Figure 3.Risk of bias analysis of postoperative studies.
PR programme characteristics.
| Reference | Group | Exercise type | Intensity | Length of intervention | Session duration | Frequency | Supervised/unsupervised | Group/individual | Inpatient/outpatient/home-based |
|---|---|---|---|---|---|---|---|---|---|
| Stefanelli et al.[ | IG | • Respiratory exercises on bench, mattress pad and wall bars, respectively; | 70% of the maximum score reached at CPET and increased by 10 W when the patient was able to tolerate the set load for 30 min | 3 weeks | 3 h | 5 sessions/week | Supervised | Individual | Out |
| CG | • Usual care – no exercise | ||||||||
| Brocki et al.[ | IG | • AT: stationary bike; | • AT: RPE 11–12 (1–4 sessions); RPE 13–16 (5–10 sessions) | 10 weeks | 15 min warm-up; 20 min aerobic exercise; 15 min muscle strength training; 10 min cool-down/relaxation | 1 session/week from 3rd week after surgery to 13th week | Supervised | Group | Out |
| CG | • Home exercises (strength training at least twice a week and a daily 30 min walk or bicycle ride with intensity of 11–12 RPE); | • Home exercises: 11–12 RPE | Home-based | ||||||
| Arbane et al.[ | IG | • AT: bicycle; | • AT: 50–60 r/min with the intensity increased steadily during the third minute to achieve a maximum of 60%−90% of heart rate reserve and to 3 or 4 on BBS and 13–15 on RPE | Length of hospital stay (about 5 days); | • AT: Starting from 5 min to 30 min in total (with 2 min warm-up and 2 min cool-down) | Daily | Supervised | Individual | In |
| CG | • Usual care – routine physiotherapy treatments, airway clearance techniques where indicated, mobilisation and upper limb activities | ||||||||
| Edvardsen et al.[ | IG | • AT: walking uphill on treadmill; | • AT: 80%−95% MHR; | 20 weeks | 1 h | • AT and ST: 3 sessions/week; | • AT and ST: Supervised; | 2 weekly sessions individual; | Out |
| CG | • Usual care – general information | ||||||||
| Cavalheri et al.[ | IG | • AT: walking along 100-m corridor or on a treadmill, or cycle ergometer[ | • AT: for corridor walking initial speed set at 80% of the average 6MWT speed; for treadmill walking, initial speed set at 70% of the average 6MWT speed. Walking speed increased when participants were able to walk 20 min continuously with symptoms and SpO2 within acceptable limits (⩾88%) | 8 weeks | 60 min | 3 sessions/week | Supervised; | Individual | Out; cycle ergometer[ |
| CG | • Usual care – no exercise | ||||||||
| Hoffman et al.[ | IG | • AT: walking in place with the Wii | • AT: 5 min during week 1 and continued to build by 5 min/day each week with the goal of walking with the Wii of 30 min/day during week 6. The duration was increased by 5 min each week if the participant’s PSE for attaining that duration was 70% or greater on a 0%−100% scale, with 100% having the highest PSE | 6 weeks | Variable: from 5 to 30 min | 5 sessions/week | Unsupervised | Individual | Home-based |
| CG | • Usual care – without exercise |
IG: intervention group; CG: control group; UL: upper limb; rep: repetitions; AT: aerobic training; IMT: inspiratory muscle training; MIP: maximal inspiratory pressure; CPT: chest physical therapy; CPET: cardiopulmonary exercise test; ST: strength training; RPE: Borg rating of perceived exertion; SPACE: Self-management Programme of Activity, Coping and Education; COPD: chronic obstructive pulmonary disease; BBS: Borg CR10 Breathlessness Scale; RM: repetition maximum; MHR: maximum heart rate; 6MWT: Six-Minute Walk Test; PSE: perceived self-efficacy.
In the event that a participant could only attend two supervised sessions per week, they were provided with a cycle ergometer (OBK600A; Orbit fitness equipment, Perth, WA, Australia) to use at home for one training session per week.
Outcome measures.
| Reference | PRE/POST | Exercise capacity | HRQoL |
|---|---|---|---|
| Stefanelli et al.[ | PRE | VO2 peak (CPET) | |
| Hoffman et al.[ | POST | 6MWT | SF-36 |
| Cavalheri et al.[ | POST | 6MWT and VO2 peak (CPET) | SF-36 + FACT-L + EORTC QOL C-30 |
| Edvardsen et al.[ | POST | VO2 peak (treadmill) | SF-36 + EORTC QOL C-30 dyspnoea |
| Arbane at al.[ | POST | ISWT | SF-36 + EORTC QOL-LC13 |
| Brocki et al.[ | POST | 6MWT | SF-36 |
PRE: preoperative; POST: postoperative; HRQoL: health-related quality of life; CPET: cardiopulmonary exercise test; 6MWT: Six-Minute Walk Test; SF-36: Short Form 36; FACT-L: Functional Assessment of Cancer Therapy – Lung scale; EORTC QOL: European Organisation for Research and Treatment of Cancer Quality Of Life; ISWT: Incremental Shuttle Walk Test.
SF-36 data.
| Reference | Assessment | IG | CG | Between-group difference (95% CI) | p value IG-CG | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | Mean ± SD | Mean change from baseline ± SD | 95% CI | N | Mean ± SD | Mean change from baseline ± SD | 95% CI | |||||
| Physical domain | Hoffman et al.[ | Baseline (before surgery) | 37 | 48.02 ± 9.3 | 35 | 46.1 ± 9.2 | 0.35 | |||||
| Post-surgery | 37 | 30.2 | 35 | 32.7 | NR | |||||||
| 3 weeks post-surgery | 37 | 41.5[ | 35 | 35.5[ | NR | |||||||
| 6 weeks post-surgery | 37 | 45.2 | 35 | 38.8 | NR | |||||||
| Cavalheri et al.[ | Baseline (6–10 weeks post-surgery) | 9 | 46 ± 6 | 2 (−3 to 6) | 8 | 42 ± 5 | −2 (−7 to 2) | NR | ||||
| 8 weeks after baseline | 9 | 48 ± 8 | 8 | 40 ± 9 | 4 (−2 to 10) | 0.20 | ||||||
| Edvardsen et al.[ | Baseline (4–6 weeks post-surgery) | 30 | 48.3 ± 9 | 31 | 48.3 ± 11.9 | NR | NS | |||||
| After PR (20 weeks) | 30 | 51.8 ± 5.5 | 31 | 43.3 ± 11.3 | 0.006 | |||||||
| Arbane et al.[ | 4 weeks post-surgery | 40 | 17 | 8.5–26.2 | 38 | 23 | 10.3 to 35.8 | 12 (0.5–23) | 0.04 | |||
| Brocki et al.[ | Baseline (3 weeks post-surgery) | 41 | 38.88 ± 10 | 37 | 38.99 ± 7 | NR | NR | |||||
| 4 months after baseline | 32 | 6.7 ± 8 | 35 | 3.1 ± 9.2 | 3.76 (−0.1 to 7.62) | 0.06 | ||||||
| 1 year after baseline | 27 | 5.1 ± 11.1 | 31 | 7.7 ± 8.5 | −1.5 (−5.6 to 2.5) | 0.27 | ||||||
| Mental domain | Hoffman et al.[ | Baseline (before surgery) | 37 | 48.1 ± 10.6 | 35 | 50 ± 10.4 | 0.46 | |||||
| Post-surgery | 37 | 51.5[ | 35 | 44.5[ | NR | |||||||
| 3 weeks post-surgery | 37 | 52.5[ | 35 | 47.4 | NR | |||||||
| 6 weeks post-surgery | 37 | 57.5 | 35 | 47 | NR | |||||||
| Cavalheri et al.[ | Baseline (6–10 weeks post-surgery) | 9 | 55 ± 6 | −4 (−12 to 5) | 8 | 46 ± 6 | 5 (−2 to 12) | NR | ||||
| 8 weeks after baseline | 9 | 51 ± 14 | 8 | 51 ± 8 | −8 (−18 to 2) | 0.10 | ||||||
| Edvardsen et al.[ | Baseline (4–6 weeks post-surgery) | 30 | 46.4 ± 11.1 | 31 | 45.4 ± 12.1 | NR | NS | |||||
| After PR (20 weeks) | 30 | 55.5 ± 5.3 | 31 | 46.6 ± 14 | 0.020 | |||||||
| Arbane et al.[ | 4 weeks post-surgery | 40 | 2 | −11.2 to 14.3 | 38 | 15 | 0.8 to 30 | 20 (4.6 to 34.6) | 0.01 | |||
| Brocki et al.[ | Baseline (3 weeks post-surgery) | 41 | 45.67 ± 10 | 37 | 44.88 ± 9 | NR | NR | |||||
| 4 months after baseline | 32 | 4.4 ± 10.4 | 35 | 5.4 ± 9.4 | −0.03 (−3.7 to 3.6) | 0.99 | ||||||
| 1 year after baseline | 27 | 5.33 ± 8.7 | 31 | 9.6 ± 9 | −2.15 (−6 to 1.7) | 0.27 | ||||||
IG: intervention group; CG: control group; SD: standard deviation; CI: confidence interval; NR: not reported; NS: not significant.
Data estimated, presented graphically.
Data refer to the subgroup with airflow obstruction.
| S1. | exp Lung Neoplasms/ |
| S2. | lung cancer.mp. |
| S3. | lung neoplasm*.mp. |
| S4. | Non-Small-Cell Lung.mp. |
| S5. | 1 or 2 or 3 or 4 |
| S6. | exp Exercise/ |
| S7. | exp Exercise Therapy/ |
| S8. | exp Physical Fitness/ |
| S9. | exp Rehabilitation/ |
| S10. | exp Physical Therapy Modalities/ |
| S11. | exercise.mp. |
| S12. | physical activity.mp. |
| S13. | physical fitness.mp. |
| S14. | rehabilitation.mp. |
| S15. | exercise therapy.mp. |
| S16. | 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 |
| S17. | exp General Surgery/ |
| S18. | exp Pulmonary Surgical Procedures/ |
| S19. | exp Thoracic Surgical Procedures/ |
| S20. | exp Surgical Procedures, Operative/ |
| S21. | surg*.mp. |
| S22. | operat*.mp. |
| S23. | resection.mp. |
| S24. | lobectomy.mp. |
| S25. | 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 |
| S26. | 5 and 16 and 25 |
| S27. | remove duplicates from 26 |
Note that the suffix exp = exploded term, / = MeSH and mp. = title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept and unique identifier (free-text term).
| Item | Authors’ judgement | Description |
|---|---|---|
|
| ||
| Sequence generation | Unclear | Quote: ‘Patients were randomly assigned to two groups’ |
| Allocation concealment | Unclear | Quote: ‘Patients were randomly assigned to two groups’ |
| Blinding of participants and personnel | High risk | Open label |
| Blinding of outcome assessment | Low risk | Comment: blinding of outcome assessment is not reported but the outcomes considered in our review (VO2 peak, FEV1, FVC, DLCO) are not likely to be influenced by lack of blinding |
| Incomplete outcome data | High risk | No defined number of patients at the follow-up |
| Selective reporting | High risk | FVC data not reported |
| Other bias | High risk | Number of patients in IG and CG are not reported |
|
| ||
| Sequence generation | Low risk | Quote: ‘A random-number table was generated by the team statistician to identify whether the potential participant was assigned to the IG or CG. The random-number table included decimal numbers between 0 and 1’. |
| Allocation concealment | Low risk | Quote: ‘The random allocation was a predefined assigned slot when a patient enrolled in the study. The recruiter used the next available predefined slot for allocation’ |
| Blinding of participants and personnel | High risk | Open label |
| Blinding of outcome assessment | Low risk | Assessors were not blinded to patient’s group allocation but outcomes considered in this study and extracted for our review (6MWT, SF-36) are not likely to be influenced by lack of blinding |
| Incomplete outcome data | Low risk | Quote: ‘All analyses were completed on the randomized groups by intent to treat’ |
| Selective reporting | High risk | 6MWT and SF-36 data are reported incompletely |
| Other bias | Low risk | Study appears to be free of other sources of bias |
|
| ||
| Sequence generation | Low risk | Quote: ‘The randomisation sequence was generated and managed by an independent researcher using a computer …’ |
| Allocation concealment | Low risk | Quote: ‘… and concealed using sequentially numbered opaque envelopes’ |
| Blinding of participants and personnel | High risk | Open label |
| Blinding of outcome assessment | Low risk | Assessors were blinded to patient’s group allocation. |
| Incomplete outcome data | Low risk | Quote: ‘Analyses were undertaken according to the intention-to-treat principle’ |
| Selective reporting | Low risk | All pre-specified outcomes were reported |
| Other bias | Low risk | Study appears to be free of other sources of bias |
|
| ||
| Sequence generation | Low risk | Quote: ‘The randomisation was done in blocks with varying block size (4–6 subjects)’ |
| Allocation concealment | Low risk | Quote: ‘… put into sealed opaque envelopes generated by an external statistician’ |
| Blinding of participants and personnel | High risk | Open label |
| Blinding of outcome assessment | Low risk | Quote: ‘… single-blind single-centre randomised controlled trial’; ‘… we cannot rule out the possibility that the technicians were not blinded during the last data collection’ |
| Incomplete outcome data | Low risk | Missing data have been imputed using intention-to-treat analysis |
| Selective reporting | Low risk | All pre-specified outcomes were reported |
| Other bias | Low risk | Study appears to be free of other sources of bias |
|
| ||
| Sequence generation | Low risk | Quote: ‘The randomisation sequence was created using StataVersion 9.0 (StataCorp, College Station, TX, USA) and was stratified by centre with a 1:1 allocation using random block sizes of two, 4 and six. … The online randomisation service provided by the Mental Health and Neurosciences Clinical Trials Unit supplied by King’s College London’ |
| Allocation concealment | Low risk | Quote: ‘The allocation sequence was concealed from the researcher who enrolled and assessed the participants. … This prevent foreknowledge of treatment assignment, and thus shielded those who recruited participants from being influenced by this knowledge’ |
| Blinding of participants and personnel | High risk | Quote: ‘The study was open labelled; neither the participants nor the researchers were blinded’. |
| Blinding of outcome assessment | Low risk | The allocation sequence was concealed from the researcher who enrolled and assessed the participants |
| Incomplete outcome data | Low risk | Missing data have been imputed using appropriate methods |
| Selective reporting | High risk | Shuttle walk test and EORTC data are reported incompletely |
| Other bias | Low risk | The study appears to be free of other sources of bias |
|
| ||
| Sequence generation | Low risk | Quote: ‘Computer-generated randomization tables, stratified for pneumonectomy (expected low performance status) were used’. |
| Allocation concealment | Low risk | Quote: ‘Individual allocations were placed in consecutively numbered and sealed opaque envelopes by an external person’ |
| Blinding of participants and personnel | High risk | Open label |
| Blinding of outcome assessment | Low risk | Assessors were blinded to the patient’s group allocation |
| Incomplete outcome data | Low risk | Analyses were based on an intention-to-treat approach, assuming that each individual adhered to their assigned treatment at each time point |
| Selective reporting | Low risk | All pre-specified outcomes were reported |
| Other bias | Low risk | The study appears to be free of other sources of bias |
FEV1: forced expiratory volume in first second; DLCO: diffusing lung capacity of carbon monoxide; FVC: functional vital capacity; IG: intervention group; CG: control group; 6MWT: Six-Minute Walk Test; SF-36: Short Form 36; EORTC: European Organisation for Research and Treatment of Cancer.
| Reference – exercise capacity | Assessment | IG | CG | p value IG-CG | ||||
|---|---|---|---|---|---|---|---|---|
| N | Mean ± SD | p value | N | Mean ± SD | p value | |||
| Stefanelli et al.[ | Baseline | NR | 14.9 ± 2.3 | <0.001 | NR | 14.8 ± 1.4 | NS | NS |
| Before surgery | 17.8 ± 2.1 | 14.5 ± 1.2 | <0.001 | |||||
| 60 days post-surgery | 15.1 ± 2.4 | <0.001 versus T1 | 11.4 ± 1.2 | <0.001 versus T0 and T1 | <0.01 | |||
IG: intervention group; CG: control group; SD: standard deviation; NS: not significant; NR: not reported.
| Reference – exercise capacity | Assessment | IG | CG | Between-group difference (95% CI) | p value IG-CG | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | Mean change from baseline ± SD | Mean ± SD | MD (95% CI) | N | Mean change from baseline ± SD | Mean ± SD | MD (95% CI) | |||||
| Hoffman et al.[ | Baseline (before surgery) | 37 | 365 ± 91 | NR | 35 | 407 ± 64 | NR | 0.03 | ||||
| Post-study (6 weeks post-surgery) | 37 | +15% (SD, 15%) | 35 | −21% (SD, 19%) | <0.001 | |||||||
| Cavalheri et al.[ | VO2 peak (L/min) | Baseline (6–10 weeks post-surgery) | 6 | 0.96 ± 0.22 | 0.14 (−0.01 to 0.28) | 8 | 1.08 ± 0.40 | −0.05 (−0.15 to 0.05) | NR | |||
| 8 weeks after baseline | 6 | 1.96 ± 0.28 | 8 | 1.03 ± 0.30 | 0.2 (0.03 to 0.33) | 0.02 | ||||||
| 6MWT (m) | Baseline (6–10 weeks post-surgery) | 6 | 540 ± 71 | 45 (6 to 83) | 8 | 477 ± 78 | −8 (−36 to 20) | NR | ||||
| 8 weeks after baseline | 6 | 585 ± 77 | 8 | 496 ± 105 | 52 (12 to 93) | 0.02 | ||||||
| Edvardsen et al.[ | Baseline (4–6 weeks post-surgery) | 30 | 19.2 ± 5.1 | NR | 31 | 18.1 ± 5.5 | NR | NR | NR | |||
| After PR (20 weeks) | 30 | 23.3 ± 5.5 | 31 | 19 ± 6 | 3.4 (1.3 to 5.5) | 2 | ||||||
| Brocki et al.[ | Baseline (3 weeks post-surgery) | 41 | 427[ | NR | 37 | 407[ | NR | NR | NR | |||
| 4 months after baseline | 32 | +61 ± 52 | 34 | +55 ± 45 | 8.33 (−20 to 36.27) | 0.57 | ||||||
| 1 year after baseline | 27 | +65 ± 70 | 29 | +60 ± 45 | 1.31 (−28.18 to 30.8) | 0.93 | ||||||
| Arbane et al.[ | Arbane et al. did not report exercise capacity levels measured by ISWT clearly | |||||||||||
IG: intervention group; CG: control group; SD: standard deviation; CI: confidence interval; 6MWT: Six-Minute Walk Test; ISWT: Incremental Shuttle Walk Test; NR: not reported.
Mean.
| Physical domain | Reference | Assessment | IG | CG | Between-group difference (95% CI) | p value IG-CG | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| N | Mean change ± SD | 95% CI | N | Mean change ± SD | 95% CI | |||||
| Physical functioning | Arbane et al.[ | 4 weeks post-surgery | 40 | 9 | −3.8 to 22 | 38 | 24 | 10.5 to 36.8 | 18 (3 to 32.4) | 0.02 |
| Brocki et al.[ | Baseline (3 weeks post-surgery) | 41 | 60.37 ± 25 | 37 | 59.05 ± 23 | NR | NR | |||
| 4 months after baseline | 32 | 8.4 ± 21.3 | 35 | 6.4 ± 20.1 | 4.39 (−4 to 12.8) | 0.3 | ||||
| 1 year after baseline | 27 | 4.8 ± 24.3 | 31 | 14.5 ± 20.3 | −4.87 (−13.7 to 4) | 0.28 | ||||
| Role-physical | Arbane et al.[ | 4 weeks post-surgery | 40 | 32 | 6.7 to 56.9 | 38 | 43 | 13.8 to 72.8 | 24 (−3.8 to 52.7) | 0.13 |
| Brocki et al.[ | Baseline (3 weeks post-surgery) | 41 | 31.7 ± 29 | 37 | 36.66 ± 24 | NR | NR | |||
| 4 months after baseline | 32 | 28.1 ± 33.8 | 35 | 15 ± 27.2 | 12.04 (−1 to 25.1) | 0.07 | ||||
| 1 year after baseline | 27 | 26.4 ± 42.3 | 31 | 34.9 ± 26 | −6.93 (−20.7 to 6.99) | 0.33 | ||||
| Bodily pain | Arbane et al.[ | 4 weeks post-surgery | 40 | 28 | 13.9 to 41.7 | 38 | 28 | 12.6 to 42.7 | 3 (−13.3 to 19.5) | 0.69 |
| Brocki et al.[ | Baseline (3 weeks post-surgery) | 41 | 45.83 ± 28 | 37 | 45.51 ± 24 | NR | NR | |||
| 4 months after baseline | 32 | 30.3 ± 24.9 | 35 | 15.3 ± 34.2 | 15.3 (4 to 26.6) | 0.01 | ||||
| 1 year after baseline | 27 | 28.4 ± 24.5 | 31 | 30.8 ± 33.7 | 4.32 (−7.8 to 16.5) | 0.49 | ||||
| General health | Arbane et al.[ | 4 weeks post-surgery | 40 | 7 | 0 to 13.6 | 38 | 1 | −11.4 to 4.2 | −4 (−16.6 to 9.6) | 0.85 |
| Brocki et al.[ | Baseline (3 weeks post-surgery) | 41 | 68.32 ± 21 | 37 | 66.38 ± 19 | NR | NR | |||
| 4 months after baseline | 32 | −1.88 ± 18.7 | 35 | 1.1 ± 12.9 | −2.64 (−10.11 to 4.9) | 0.49 | ||||
| 1 year after baseline | 27 | −2.81 ± 19 | 31 | 7.74 ± 15.3 | −10.34 (−18.3 to −2.4) | 0.01 | ||||
IG: intervention group; CG: control group; SD: standard deviation; CI: confidence interval; NR: not reported.
Data refer to the subgroup with airflow obstruction.
| Mental domain | Reference | Assessment | IG | CG | Between-group difference (95% CI) | p value IG-CG | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| N | Mean change ± SD | 95% CI | N | Mean change ± SD | 95% CI | |||||
| Vitality | Arbane et al.[ | 4 weeks post-surgery | 40 | 12 | 0 to 24.6 | 38 | 13 | 1.9 to 23.4 | 7 (−5.1 to 18.3) | 0.26 |
| Brocki et al.[ | Baseline (3 weeks post-surgery) | 41 | 46.46 ± 18 | 37 | 43.24 ± 16 | NR | NR | |||
| 4 months after baseline | 32 | 15.94 ± 20 | 35 | 14.1 ± 15 | 4.65 (−2.98 to 12.3) | 0.23 | ||||
| 1 year after baseline | 27 | 12 ± 24.2 | 31 | 22.2 ± 15 | −8.48 (−16.4 to −0.6) | 0.04 | ||||
| Social functioning | Arbane et al.[ | 4 weeks post-surgery | 40 | 2 | −17 to 21.5 | 38 | 10 | −10 to 30 | 18 (−5.5 to 41) | 0.13 |
| Brocki et al.[ | Baseline (3 weeks post-surgery) | 41 | 73.78 ± 27 | 37 | 73.65 ± 30 | NR | NR | |||
| 4 months after baseline | 32 | 13.3 ± 24.4 | 35 | 9.3 ± 31.9 | 3.7 (−5.8 to 13.2) | 0.44 | ||||
| 1 year after baseline | 27 | 14.81 ± 27.5 | 31 | 19.35 ± 26.8 | −2.01 (−12 to 7.8) | 0.67 | ||||
| Role-emotional | Arbane et al.[ | 4 weeks post-surgery | 40 | 3 | −40.6 to 34.5 | 38 | 42 | 0.1 to 84.3 | 45 (−0.2 to 89.2) | 0.05 |
| Brocki et al.[ | Baseline (3 weeks post-surgery) | 41 | 56.91 ± 36 | 37 | 53.6 ± 33 | NR | NR | |||
| 4 months after baseline | 32 | 12.5 ± 43.4 | 35 | 20.7 ± 31.5 | −11.93 (−14 to 10.1) | 0.75 | ||||
| 1 year after baseline | 27 | 21 ± 41.4 | 31 | 36.81 ± 35 | 3.39 (−16.3 to 9.5) | 0.61 | ||||
| Mental health | Arbane et al.[ | 4 weeks post-surgery | 40 | −8 | −15.5 to −0.5 | 38 | 2 | −9.3 to 13.6 | 8 (−3.3 to 18.5) | 0.16 |
| Brocki et al.[ | Baseline (3 weeks post-surgery) | 41 | 60.76 ± 18 | 37 | 60.97 ± 17 | NR | NR | |||
| 4 months after baseline | 32 | 9 ± 18.9 | 35 | 6.6 ± 19.3 | 3.77 (−2.7 to 110.2) | 0.25 | ||||
| 1 year after baseline | 27 | 7.6 ± 13.3 | 31 | 14.8 ± 16.2 | −3.6 (−10.4 to 3.2) | 0.3 | ||||
IG: intervention group; CG: control group; SD: standard deviation; CI: confidence interval; NR: not reported.
Data refer to the subgroup with airflow obstruction.
| Assessment | IG | CG | p value IG-CG | |||||
|---|---|---|---|---|---|---|---|---|
| N | Mean | SD | N | Mean | SD | |||
| Dyspnoea | Baseline (4–6 weeks post-surgery) | 30 | 33.3 | NR | 31 | 33.3 | NR | NS |
| After PR (20 weeks) | 30 | 37 | 25.3 | 31 | 58 | 32.1 | 0.03 | |
IG: intervention group; CG: control group; SD: standard deviation; CI: confidence interval; NR: not reported; NS: not significant; NR: not reported.